Metal-based nanoparticles for cardiovascular disease diagnosis and therapy
作者机构：State Key Laboratory of Molecular Vaccinology and Molecular DiagnosticsCenter for Molecular Imaging and Translational MedicineSchool of Public HealthXiamen UniversityXiamen 361102China Department of PharmacyXiamen Medical CollegeXiamen 361023China
出 版 物：《Particuology》 (颗粒学报（英文版）)
年 卷 期：2023年第72卷第1期
页 面：94-111页
核心收录：
学科分类：1002[医学-临床医学] 0817[工学-化学工程与技术] 0805[工学-材料科学与工程（可授工学、理学学位）] 100214[医学-肿瘤学] 10[医学]
基 金：supported by the Major State Basic Research Development Program of China(grant No.2017YFA0205201) the National Natural Science Foundation of China(grant Nos.81801817,81901876,and U1705281) the Fundamental Research Funds for the Central Universities(grant Nos.20720190088 and 20720200019) Fujian Undergraduate Training Program for Inno-vation and Entrepreneurship(grant Nos.201812631010,JT180649,and HXJB-08) the Program for New Century Excellent Talents in University,China(grant No.NCET-13-0502).
主 题：Metal-based nanoparticles Nanomedicine Cardiovascular diseases Diagnosis Therapy
摘 要：Cardiovascular diseases (CVDs) are the most prominent cause of disability and mortality in the world. Although there have been a variety of therapeutic options for the management of CVDs, most of the traditional therapeutic strategies could not sufficiently stop or reduce the progression of these diseases and may result in some side effects. With the advance in nanotechnology, a number of metal-based nanoparticles have been developed and shown promising potentials in the treatment of CVDs. In this review, we provide a comprehensive review of researches on recent development of metal-based nanoparticles in diagnosis and therapy in CVDs as biomedical materials. We also discuss the challenges in the clinical translation and potential risks in their application of CVD therapy. Based on the ongoing research and applications, we can conclude metal-based nanoparticles are expected to become potential therapeutics for the treatment of CVDs. But their application is still in its infancy and much more efforts should be made to enforce a clinical breakthrough.
维普期刊数据库